Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $230

Benzinga · 3d ago
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $221 to $230.